https://www.selleckchem.com/pr....oducts/gsk2879552-2h
ly available staging tools and tumor DNA sequencing cannot identify such patients reliably and accurately. This study highlights the inaccuracy of post-NAC clinical restaging TUR with or without adjunctive tumor mutation analysis, to assess pathologic residual disease accurately. Caution must be taken when performing post-NAC restaging, especially when considering conservative management strategies such as active surveillance on this basis. Patient summary Several groups are evaluating whether certain patients, whose bladder can
Like
Comment
Share
